@FiercePharma: Novartis nixes $78M non-compete with Chairman Vasella amid frenzy of criticism from Swiss. Report | Follow @FiercePharma
@EricPFierce: Gilead recall raises question about Vistide stocks. Company tells providers to look to generic suppliers. Story | Follow @EricPFierce
@AlisonBFierce: Court: Sanofi is not liable to pay local capital gains tax for its 30B rupee acquisition of Indian vax maker Shantha. More | Follow @AlisonBFierce
> The planned closure of a GlaxoSmithKline ($GSK) financial services operation in Cork, Ireland, is moving ahead, with 94 local jobs to be cut; staffers will be offered the choice of relocating to the operation's new home in the U.K. Report
> Bayer and Regeneron ($REGN) plan to launch new studies of their vision-loss treatment VEGF Trap-Eye in diabetic macular edema patients in China, Russia and other Asian countries; the drug is sold as Eylea in the U.S. Report
> Sanofi's ($SNY) Indian unit wants to double its share of the consumer healthcare business in that country to 4.2% of the 27 billion rupee ($497 million) market. Report
> Actelion ($ATLN) won Japanese approval for the pulmonary arterial hypertension (PAH) treatment epoprostenol "ACT," marketed as Veletri in the U.S. Report
> Low growth in Medicare drug spending has allowed the Part D program to lower copayments and standard deductibles. Report
> FDA issued warning letters to 9 internet distributors of dietary supplements, citing false claims about their products' flu-fighting properties. Report
Biotech News
@FierceBiotech: Pfizer axes CovX research unit and 100 jobs in San Diego. More | Follow @FierceBiotech
@JohnCFierce: Coronavirus, which killed 5 of the 12 people known to have been infected by it, is suited to spread easily in humans. Report | Follow @JohnCFierce
> Gilead races to FDA after hep C blockbuster hopeful scores 4th win in PhIII. Story
> Roche grabs rights to Chiasma's PhIII rare disease drug in $595M deal. Article
> Analysts assign Phytopharm to scrap heap after decisive Parkinson's failure. News
Pharma News
@FiercePharma: Novartis nixes $78M non-compete with Chairman Vasella amid frenzy of criticism from Swiss. Report | Follow @FiercePharma
@EricPFierce: Gilead recall raises question about Vistide stocks. Company tells providers to look to generic suppliers. Story | Follow @EricPFierce
@AlisonBFierce: Court: Sanofi is not liable to pay local capital gains tax for its 30B rupee acquisition of Indian vax maker Shantha. More | Follow @AlisonBFierce
> GSK, Roche teaming with anti-doping agency. Report
> Novartis nabs another FDA-approved indication for everolimus. More
> Takeda preps for first Actos trial now opening in LA. News
@FierceMedDev: PolyActiva pulls in $9.5M for intraocular implant work. Story | Follow @FierceMedDev
@MarkHFierce: AutoGenomics aborted its second IPO attempt in a few years. The company promises #3, but we'll see. More | Follow @MarkHFierce
@DamianFierce: In case you missed it over the weekend, Quintiles is finally kicking off the process of going public. News | Follow @DamianFierce
> Medtronic rides emerging markets growth to strong quarter. Story
> NeuroMetrix eyes sales rep expansion for pain device rollout. Article
Biotech Research News
> Antidepressant could reverse sickle cell disease. More
> Nicotinamide slows breast tumor growth in mice. Story
> Human stem cell trial set to begin in Japan. Item
> Compound could restore learning, memory in Angelman syndrome. Article
CRO News
> QPS swings into North Carolina with Hamner partnership. Story
> Charles River predicts strong 2013 despite Q4 slump. More
> With revenue rolling, AMRI looks to CDMO boom in 2013. Article
> Quintiles files IPO worth $600 million--or much more. News
Biotech IT News
> Genomics? There could be an app for that. Item
> Boehringer Ingelheim goes to Hungary for R&D software. More
> EU enters expensive race to map out brain secrets with computers. Article
> CLC bio capitalizes on surge in DNA sequencing. Story
Pharma Manufacturing News
> AMRI 'money pit' now money maker. Item
> GSK commits to continuous processing. More
> Gilead recalls some Vistide; supplies may be an issue. Article
> FDA lambastes Jamaican manufacturer over sterility, quality. Story
And Finally... Scientists created new strains of polio vaccine designed to protect workers in factories where the immunizations are made. Report